Darzalex (daratumumab) Approved by FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
HORSHAM, PA, Nov. 21, 2016 – Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.1 Clinical studies have shown that Darzalex, in combination with lenalidomide (an immunomodulatory agent) and dexamethasone, reduced the risk of disease progression or death by 63 percent, compared to lenalidomide and dexamethasone alone, in patients with multiple myeloma who received a median of one prior therapy (Hazard Ratio [HR]=0.37; 95 percent CI [0.27, 0.52], p<0.0001).1 In combination with bortezomib (a proteasome inhibitor [PI]) and dexamethasone, Darzalex reduced the risk of disease progression or death by 61 percent, compared to bortezomib and dexamethasone alone, in patients with multiple myeloma who received a median of two prior lines of therapy (HR=0.39; 95 percent CI [0.28, 0.53], p<0.0001).1 Multiple myeloma is an incurable blood cancer that occurs when malignant plasma cells grow uncontrollably in the bone marrow.2,3
The approval comes three months after a supplemental Biologics License Application (sBLA) was submitted to the FDA in August 2016.4 Darzalex received Breakthrough Therapy Designation from the FDA for this indication in July 2016.5
“While tremendous progress in the treatment of multiple myeloma has been made in the past decade, patients and their physicians continue to need new treatment options,” said Meletios A. Dimopoulos, M.D., Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece, a Darzalex clinical trial investigator. “With Darzalex, we have a potential new backbone therapy, which has shown pronounced efficacy as either a single agent or in combination with standard of care regimens. The addition of Darzalex also significantly improved progression-free survival in combination with two of the most widely used treatment classes, making it a versatile option for patients who have received at least one prior therapy.”
Darzalex is the first CD38-directed cytolytic antibody approved anywhere in the world.6 It was first approved by the FDA in November 2015 as a monotherapy treatment for patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double refractory to a PI and immunomodulatory agent.1
Today’s approval is supported by data from two Phase 3 studies:
- According to results from the open-label POLLUX (MMY3003) clinical study, the median progression-free survival (PFS) in the Darzalex arm has not been reached, compared with a median PFS of 18.4 months for patients who received lenalidomide and dexamethasone alone, with a median follow-up of 13.5 months.1 In addition to meeting the primary endpoint of improved PFS, Darzalex significantly increased the overall response rate (ORR) [91 percent vs. 75 percent, p<0.0001], compared to lenalidomide and dexamethasone alone, including doubling rates of complete response (CR) [25 percent vs. 12 percent, p<0.0001] and significantly increasing very good partial response (VGPR) [32 percent vs. 24 percent, p<0.0001].1 These results were published in The New England Journal of Medicine, with an accompanying editorial, in October 2016.7
- According to results from the open-label CASTOR (MMY3004) clinical study, the median PFS in the Darzalex arm has not been reached, compared with a median PFS of 7.2 months for patients who received bortezomib and dexamethasone alone, with a median follow-up of 7.4 months.1 In addition to meeting the primary endpoint of improved PFS, Darzalex also significantly increased ORR [79 percent vs. 60 percent, p<0.0001], compared to bortezomib and dexamethasone alone, including doubling rates of CR [14 percent vs. 7 percent, p<0.0001] and significantly increasing VGPR [38 percent vs. 19 percent, p<0.0001].1 These results were published in The New England Journal of Medicine in August 2016.8
“The approval of daratumumab provides multiple myeloma patients with another versatile treatment option to help address their urgent medical needs,” said Paul Giusti, President and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF). “At the MMRF, we are excited by the groundbreaking work being done to bring effective, new treatments to patients.”
“We are proud of the rapid development and approval of Darzalex for use earlier in the treatment pathway, but our work does not stop here,” said Peter F. Lebowitz, M.D., Ph.D., Global Oncology Head, Janssen Research & Development, LLC. “We are only starting to uncover the full potential of this compound, and we remain committed to the continued study of daratumumab to more fully understand its utility for patients with multiple myeloma and other cancer types.”
Overall, the safety of the Darzalex combination therapy was consistent with the known safety profiles of Darzalex monotherapy (D) and lenalidomide plus dexamethasone (Rd), respectively. In data from the POLLUX trial, the most frequent (≥20 percent) adverse reactions (ARs) [DRd/Rd] were infusion reactions (48 percent/0 percent), diarrhea (43 percent/25 percent), nausea (24 percent/14 percent), fatigue (35 percent/28 percent), pyrexia (20 percent/11 percent), upper respiratory tract infection (65 percent/51 percent), muscle spasms (26 percent/19 percent), cough (30 percent/15 percent) and dyspnea (21 percent/12 percent).1 The overall incidence of serious ARs was 49 percent (DRd) compared with 42 percent (Rd).1 Serious ARs (Grade 3/4) – which had at least a 2 percent greater incidence in the DRd arm compared to the Rd arm – were pneumonia (12 percent/10 percent), upper respiratory tract infection (7 percent/4 percent), influenza (3 percent/1 percent) and pyrexia (3 percent/1 percent).1 Seven percent/8 percent of patients discontinued therapy due to an AR.1 The most common treatment-emergent hematology laboratory abnormalities [DRd/Rd] were lymphopenia (95 percent/87 percent), neutropenia (92 percent/87 percent), thrombocytopenia (73 percent/67 percent) and anemia (52 percent/57 percent).1 The most common Grade 3/4 treatment-emergent hematology laboratory abnormalities were neutropenia (53 percent/40 percent), lymphopenia (52 percent/38 percent), thrombocytopenia (13 percent/15 percent) and anemia (13 percent/19 percent).1
In data from the CASTOR study, the safety of the Darzalex combination therapy was consistent with the known safety profiles of Darzalex monotherapy (D) and bortezomib plus dexamethasone (Vd), respectively. The most frequent ARs [DVd/Vd] (>20 percent) were infusion reactions (45 percent/0 percent), diarrhea (32 percent/22 percent), peripheral edema (22 percent/13 percent), upper respiratory tract infection (44 percent/30 percent), peripheral sensory neuropathy (47 percent/38 percent), cough (27 percent/14 percent) and dyspnea (21 percent/11 percent).1 The overall incidence of serious ARs was 42 percent (DVd) compared with 34 percent (Vd).1 Serious ARs (Grade 3/4) – which had at least a 2 percent greater incidence in the DVd arm compared to the Vd arm – included upper respiratory tract infection (5 percent/2 percent), diarrhea (2 percent/0 percent) and atrial fibrillation (2 percent/0 percent).1 Seven percent/9 percent of patients discontinued therapy due to an AR.1 The most common treatment-emergent hematology laboratory abnormalities were thrombocytopenia (90 percent/85 percent), lymphopenia (89 percent/81 percent), neutropenia (58 percent/40 percent) and anemia (48 percent/56 percent).1 The most common Grade 3/4 treatment-emergent hematology laboratory abnormalities were lymphopenia (48 percent/27 percent), thrombocytopenia (47 percent/35 percent), neutropenia (15 percent/6 percent) and anemia (13 percent/14 percent).1
The recommended dose of Darzalex is 16 mg/kg body weight administered as an intravenous infusion.1 The dosing schedule for Darzalex in combination with lenalidomide and dexamethasone begins with weekly administration (weeks 1-8) and reduces in frequency over time to every two weeks (weeks 9-24) and ultimately every four weeks (week 25 onwards) until disease progression.1 The dosing schedule for Darzalex in combination with bortezomib and dexamethasone begins with weekly administration (weeks 1-9) and reduces in frequency over time to every three weeks (weeks 10-24) and ultimately every four weeks (weeks 25 and onwards) until disease progression.1
In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize Darzal>ex.99
About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenUS and www.twitter.com/JanssenGlobal.
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding DARZALEX’s potential and further development of daratumumab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Biotech, Inc., Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges inherent in product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products or new indications; manufacturing difficulties or delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
2 Kumar, SK et al. Leukemia. 2012 Jan; 26(1):149-57.
3 American Cancer Society. "Multiple Myeloma Overview." Available at: http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma. Accessed November 2015.
4 Janssen Biotech, Inc. “Janssen Submits Application to U.S. FDA to Expand Indication for Daratumumab (DARZALEX®).” Issued August 17, 2016.
5 Janssen Research & Development, LLC. “Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma.” Issued July 25, 2016.
6 Janssen Biotech, Inc. “DARZALEX (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of multiple Myeloma.” Issued November 16, 2015.
7 Dimopoulos, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375:1319-1331.
8 Palumbo, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375:754-766.
9 Janssen Biotech, Inc. “Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab.” Issued August 30, 2012.
Source: Janssen Biotech, Inc.
Posted: November 2016
- Genmab Announces U.S. FDA Approval of Darzalex (daratumumab) in Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma - June 16, 2017
- FDA Approves Darzalex (daratumumab) for Patients with Previously Treated Multiple Myeloma - November 16, 2015
- U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma - September 4, 2015
- Janssen Initiates Rolling Submission of BLA for Daratumumab for the Treatment of Multiple Myeloma - June 5, 2015
- Genmab Announces Preliminary Results in Phase II Study of Daratumumab in Double Refractory Multiple Myeloma - February 3, 2015
- Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma from U.S. FDA - May 1, 2013
- Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab - August 30, 2012